Dr. Amit Oza is Head of the Division of Medical Oncology & Hematology, and Medical Director of the Cancer Clinical Research Unit at Princess Margaret (PM) Cancer Centre. He is also co-Director of the Drug Development Program at PM Cancer Centre, Scientist at the Ontario Cancer Institute, and Professor of Medicine at University of Toronto. Dr. Oza has been PI and co-investigator in >100 phase I, II and III trials for gynecological cancer and advanced colorectal malignancies. He is the past co-chair of the National Cancer Institute Gynecologic Cancer Steering Committee, and Executive Member of the international Gynecologic Cancer InterGroup. Under his direction, the gynecology group is one of the largest ovarian cancer (OC) clinical trials groups consistently accruing >30% of all patients seen onto clinical trials (>120/yr) at PM Cancer Centre. Under his direction the group has participated or led seminal studies in gynecologic cancers that have led to the approval or use of targeted agents such as PARP inhibitors (olaparib, niraparib) and anti-angiogenic agents (bevacizumab) internationally. Since 2011, he has obtained >$36.9M in peer-reviewed funding and has published >180 articles (all types) in journals, including the New England Journal of Medicine (IF=53); Lancet Oncology (IF=16), and the Journal of Clinical Oncology (IF=16.4).
Amit M Oza
Gynecol Oncol. 2014 Aug 27;
Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing.
Cancer. 2014 Jul 31;
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol. 2014 Jul;15(8):799-808
A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia.
Gynecol Oncol. 2014 Aug;134(2):274-80
Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
Int J Gynecol Cancer. 2014 Jun;24(5):865-73
J Natl Cancer Inst. 2014 Apr;106(4):dju029
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.
Leuk Lymphoma. 2014 Apr 22;
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Cancer. 2014 Feb 15;120(4):603-10
Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.
Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer.
Gynecol Oncol. 2013 Nov;131(2):315-20
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Co-director, Robert and Maggie Bras and Family Drug Development Program
Professor, Department of Medicine, University of Toronto
Head, Department of Medical Oncology & Hematology